BRCA1 and prostate carcinoma: We found ten patients (19.6%) fulfilling the inclusion criteria used in the PROfound clinical trial of PARP inhibitors (PARPi) in prostate cancer, with eight of these (15.7%) showing biallelic loss of one of the 15 genes included in the trial, while five patients (9.8%) harbored well documented pathogenic alterations of BRCA1/2 specifically (Fig. 2b, Supplementary Table 3, Supplementary Data 2 and Supplementary Data 3).